^
    almost4years
    [VIRTUAL] TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase (AACR-II 2020)
    IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments.
    P1 data • PARP Biomarker
    |
    CD44 (CD44 Molecule)
    |
    Cantrixil (TRX-E-002-1)
    4years
    Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov)
    P1, N=28, Completed, Kazia Therapeutics Limited | Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Mar 2020
    Clinical • Trial completion • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    Cantrixil (TRX-E-002-1)